This message contains images. If you don't see images, click here to view.
Advertise in this news brief.



Text Version   RSS   Subscribe   Unsubscribe   Archive   Media Kit |  Histology Marketplace:     

Home   History   Meeting Calendar   Career Center   Certification   Contact Us    



 




NSH NEWS

Keynote lecture at the NSH 41st Annual Symposium Convention
NSH
David Merritt, former chairman of the Center for Health Transformation and expert on healthcare policy, managing director at Luntz Global Partners will present The Future of Healthcare, Aug. 30. Learn more.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


CFA Culling Memorial Lecture: Brilliant Blunders: From Darwin to Einstein
NSH
Presented by Dr. Mario Livio, best-selling author, senior astrophysicist, Hubble Space Telescope Science Institute, Aug. 31. Learn more.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


PRODUCT SHOWCASE
  GBI Cost Effective Products

GBI Labs produces the largest selection of secondary detection kits, from single to multiple detection kits, with wide range host species. We provide FREE samples to 1st time users. Staining with our kits results in similar or better sensitivity than other detection kits on the market with 20%-30% cost less.
 


July 22 laboratory webinar — How to Integrate HistoQIP into a Quality Management Program
NSH
Quality assurance involves continuous monitoring of technical and medical procedures and is an essential part of a well-developed quality management program. The Histology Quality Improvement Program (HistoQIP) allows the user to monitor the quality of technical work performed and compare the quality to recognized standards and peers. In addition, HistoQIP provides referenced solutions to common problems allowing for quality improvement changes for identified quality variances. Register now.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Important information from ASCP Board of Certification
NSH
ASCP has released a new statement about lapsed or expired certifications. Were you certified on or after Jan. 1, 2004? Have you maintained your certification by completing the Credential Maintenance Program? If not, it is strongly urged that you to begin the reinstatement process now. Click here about reinstatement policy.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article




One-day Histology Forum for the veterinary and research scientist
NSH
NSH will be offering a one-day Veterinary, Industry and Research Forum on Nov. 1 in conjunction with the 2015 Annual AALAS Meeting in Phoenix. The forum was developed for NSH members and AALAS attendees and will address histology techniques and applications that directly impact daily work improving the quality of study data as well as improve the knowledge base and skill set for scientists and investigators performing histology related functions as part of their job.

The focus is on histologic techniques and applications specific to working with animals in veterinary and research laboratories. Sessions will provide high level troubleshooting advice covering necropsy, fixation's impact on microtomy, special stains, In-Situ Hybridization and Immunohistochemistry. The day will conclude with a discussion of comparative histology addressing the use and translation of animal models of human diseases. The forum will encourage active dialogue and is a great opportunity to expand your professional network to continue the exchange of ideas upon returning to your lab. Learn more.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


TOP STORIES


Canadian researchers launch world's 1st viral therapy clinical trial to attack and kill cancer cells
News-Medical.Net
Canadian researchers have launched the world's first clinical trial of a novel investigational therapy that uses a combination of two viruses to attack and kill cancer cells and stimulate an anti-cancer immune response. Previous research by this team and others worldwide suggests that this approach could be very powerful, and could have fewer side effects than conventional chemotherapy and radiation, although it will take years to rigorously test through this trial and others.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


PRODUCT SHOWCASE
  Hassle Free Block Storage Cabinet

Avantik Biogroup is proud to introduce another Customer Requested Quality Innovation for Histology...the Avantik Biogroup Block Storage Cabinet! We introduced Hassle-Free Drawer Technology with Interlocking Stackability and More Clearance between the top of the blocks and the drawers to achieve the industry's first Jam-Free, Hassle-Free Block Storage Cabinet!
 


Why rapid onboarding isn't always right
Lab Manager
Mark Lanfear writes: "'Rapid onboarding,' as it's commonly called, is thought by many to be necessary because the faster recruits get acclimated to your system so they can do the job you're paying them to do, the better. After all, time is money. While I can't argue with that logic, I believe there are other ways to achieve higher workforce efficiency and ROI. And to my way of thinking, focusing on smart talent supply chain management instead of speed may be a better solution, especially in the life science industry."
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Harvard University researchers turn bubble wrap into tiny test tubes that could be used for clinical pathology lab testing in developing nations
Dark Daily
By turning bubble wrap into a cheap alternative to glass test tubes and culture dishes, Harvard University scientists may have found a way to cushion clinical laboratories in developing countries from the high cost of basic lab gear. This latest discovery is significant because it adds to the growing number of in vitro diagnostic testing systems that potentially can generate results as accurate as those produced in today's state-of-the-art medical laboratories, but at a much lower cost.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




Drug trials are coming to an iPhone near you
Think Progress
Two of the world's top pharmaceutical companies are looking to Apple users for their next drug trials. GlaskoSmithKline and Purdue Pharma are planning to roll out clinical drug trials using ResearchKit, Apple's open-source app software that lets the scientists and medical researchers conduct and keep track of clinical trial subjects through their smartphones.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


IN THE NEWS


Chemists develop novel drug to fight malaria
University of Washington via Medical Xpress
An international team of scientists — led by researchers from the University of Washington and two other institutions — has announced that a new compound to fight malaria is ready for human trials. In a new paper published July 15 in Science Translational Medicine, they show that this compound is the first to cripple a critical protein that the malaria parasite needs to survive at different stages of its complex life cycle, and is suitable for clinical tests in humans.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Missed an issue of Under The Microscope? Click here to visit the Under The Microscope archive page.


Why do most clinical trials fail?
Clinical Leader
According to the latest industry research, about 90 percent of drugs that reach clinical stage development never make it to FDA approval and commercialization. At first glance, one could conclude that the reason is the stringent FDA review process designed to ensure that only products that deliver an acceptable efficacy and safety profile ever reach consumers. But a more detailed analysis of the results of many clinical research programs tells a different story.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Insights on drug discovery
Lab Manager
Most drug discovery efforts begin with a biological target — the molecule inside the body whose activity the drug is expected to enhance or diminish. Assurance that the target is pharmacologically accessible and responsible in some way for the disease in question is based on target validation studies.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Engineering a shingles vaccine that doesn't wimp out over time
NPR
The varicella zoster virus can hide in the body over a lifetime and suddenly activate, causing a painful, blistery rash. There is a vaccine on the market. The Centers for Disease Control and Prevention recommends it for people age 60 and older. But it's not very effective. It prevents shingles 64 percent of the time overall, but loses effectiveness as years go by, just when people are getting more susceptible. By the time people turn 70, the vaccine is only 38 percent effective. A new vaccine that offers nearly complete protection against the painful shingles rash may be on the market as early as 2017.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Adverse effects of clinical trial data transparency — should we worry?
University of Copenhagen via Medical Xpress
New legislation forces drug developers to disclose most of their clinical trials data when applying for approval of a new drug. Many will probably think that this is a good idea. However, too much transparency in drug development might be problematic, according to Timo Minssen, researcher at the University of Copenhagen. He warns that the new regulations might make it difficult for companies to patent new medical uses for known drugs. Without sufficient alternatives, this may inhibit the full development of new medical uses towards market approval.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


TRENDING ARTICLES
Missed last week's issue? See which articles your colleagues read most.

    University installs most powerful microscope in the US (Lab Manager)
New stem cell research uncovers causes of spinal muscular atrophy (Royal Holloway, University of London via Medical Xpress)
July 22 laboratory webinar — How to Integrate HistoQIP into a Quality Management Program (NSH)
Scanadu preparing consumer self-test device for review by FDA as part of its mission to enable patients to monitor their health without need for clinical pathology lab tests (Dark Daily)

Don't be left behind. Click here to see what else you missed.


 

Under the Microscope
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Ashley Whipple, Senior Content Editor, 469.420.2642   
Contribute news

This edition of Under the Microscope was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here -- it's free!
Recent issues
July 8, 2015
July 1, 2015
June 30, 2015 blast
June 26, 2015 blast



7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063